Secondary prevention of atherothrombosis in adults
patients who have suffered a myocardial infarction (start of treatment-a few days, but not later than 35 days after occurrence), ischemic stroke (start of treatment-7 days, but not later than 6 months after occurrence) , or who have been diagnosed with peripheral artery disease (lesion of the arteries and atherothrombosis of the vessels of the lower extremities);
patients with acute coronary syndrome:
patients with acute coronary syndrome without St segment elevation (unstable angina or myocardial infarction without q wave), including patients who had a stent installed during percutaneous coronary angioplasty, in combination with acetylsalicylic acid (aSA)
with acute myocardial infarction with St segment elevation, in combination with acetylsalicylic acid (in patients receiving standard medical treatment and who are indicated for thrombolytic therapy).
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation. Clopidogrel in combination with ASC is indicated in adult patients with atrial fibrillation who have at least one risk factor for vascular events, in which there are contraindications to treatment with Vitamins K antagonists (aVC) and who have a low risk of bleeding, for the prevention of atherothrombotic and thromboembolic events, including stroke.
For more information, see the section “Pharmacological properties”.